MetaVia Announces Updates on Obesity and Metabolic Therapies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: PRnewswire
- Management Presentation: MetaVia Inc. will present updates on its novel obesity and metabolic therapies at the Emerging Growth Conference on June 11, 2026, at 3:25 PM ET, featuring insights from CEO Hyung Heon Kim and CFO Marshall H. Woodworth, showcasing the company's innovative advancements in cardiometabolic diseases.
- DA-1726 Clinical Trial: In a Phase 1 multiple ascending dose trial for obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction, functioning as a dual agonist for GLP-1 and GCGR, potentially outperforming selective GLP-1 receptor agonists like semaglutide in weight management.
- Positive Effects of Vanoglipel: As a novel GPR119 agonist, vanoglipel showed positive effects on liver inflammation, lipid metabolism, and glucose metabolism in preclinical studies, reducing hepatic steatosis, inflammation, and fibrosis, while also demonstrating direct hepatic action in a Phase 2a clinical study.
- Virtual Conference Logistics: Attendees can submit questions in advance, and a Q&A session will follow the presentation, while those unable to join live can access an archived webcast on MetaVia's events page, enhancing investor engagement and transparency.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MTVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MTVA
Wall Street analysts forecast MTVA stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.680
Low
40.00
Averages
47.50
High
55.00
Current: 2.680
Low
40.00
Averages
47.50
High
55.00
About MTVA
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide 1, glucagon-dependent insulinotropic polypeptide receptor, and peptide YY.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MetaVia Updates on Obesity and Metabolic Therapies at Emerging Growth Conference
- Management Presentation: MetaVia Inc.'s CEO Hyung Heon Kim and CFO Marshall H. Woodworth will present the company's latest advancements in obesity and metabolic therapies at the Emerging Growth Conference on June 11, 2026, which is expected to attract investor and industry attention.
- New Drug Development: MetaVia is developing DA-1726, a novel oxyntomodulin (OXM) analogue that acts as a dual agonist for GLP-1 and GCGR, showing best-in-class potential for weight loss, glucose control, and waist reduction, potentially outperforming existing GLP-1 receptor agonists.
- Clinical Trial Results: In a Phase 1 multiple ascending dose trial for obesity, DA-1726 demonstrated superior weight loss effects, indicating a promising outlook for treating obesity and potentially providing significant market opportunities for the company.
- Metabolic Disease Treatment: MetaVia's vanoglipel (DA-1241), as a GPR119 agonist, showed positive effects on liver inflammation, lipid metabolism, and glucose metabolism in preclinical studies, potentially offering a new treatment option for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
See More
MetaVia Announces Updates on Obesity and Metabolic Therapies
- Management Presentation: MetaVia Inc. will present updates on its novel obesity and metabolic therapies at the Emerging Growth Conference on June 11, 2026, at 3:25 PM ET, featuring insights from CEO Hyung Heon Kim and CFO Marshall H. Woodworth, showcasing the company's innovative advancements in cardiometabolic diseases.
- DA-1726 Clinical Trial: In a Phase 1 multiple ascending dose trial for obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction, functioning as a dual agonist for GLP-1 and GCGR, potentially outperforming selective GLP-1 receptor agonists like semaglutide in weight management.
- Positive Effects of Vanoglipel: As a novel GPR119 agonist, vanoglipel showed positive effects on liver inflammation, lipid metabolism, and glucose metabolism in preclinical studies, reducing hepatic steatosis, inflammation, and fibrosis, while also demonstrating direct hepatic action in a Phase 2a clinical study.
- Virtual Conference Logistics: Attendees can submit questions in advance, and a Q&A session will follow the presentation, while those unable to join live can access an archived webcast on MetaVia's events page, enhancing investor engagement and transparency.
See More
Rita Ferro Takes Charge of Disney's Global Advertising
- Leadership in Advertising: Rita Ferro, as President of Global Advertising at Disney, leverages her 29 years of industry experience to enhance the company's advertising sales across traditional TV, streaming, and digital platforms, thereby strengthening its position in a competitive media landscape.
- Strategic Integration: Ferro emphasizes the 'One Disney' strategy, creating more compelling advertising opportunities by integrating brand partnerships with movie studios and park activations, which enhances customer engagement and brand loyalty.
- International Expansion: Ferro plans to promote ad-supported streaming business internationally, particularly focusing on local content investments for Disney+, aiming to capitalize on the diversity and growth potential of international markets to drive global business development.
- Tech-Driven Approach: Ferro has spearheaded the restructuring of Disney's ad tech stack, enabling advertisers to target more effectively and improving measurement capabilities, thus enhancing the company's competitiveness in the digital advertising space.
See More
MetaVia's DA-1726 Shows Significant Weight Loss Results
- Significant Weight Loss: The 48 mg cohort achieved a mean body weight reduction of 9.1% at Day 54, with a 6.1% reduction at Day 26, indicating a sustained weight loss trend that underscores DA-1726's potential in obesity treatment.
- Waist Circumference Reduction: Participants in the 48 mg group experienced a significant waist circumference reduction of 5.8 cm at Day 26 and 9.8 cm at Day 54, demonstrating statistical significance compared to the placebo group, further supporting DA-1726's application in improving metabolic health.
- Liver Health Improvements: Exploratory FibroScan assessments indicated significant liver-related improvements in the 48 mg group at Day 54, including a reduction in controlled attenuation parameter (CAP) by 20.0 dB/m, suggesting DA-1726's positive impact on metabolic dysfunction-associated steatohepatitis (MASH).
- Good Tolerability: DA-1726 showed favorable tolerability at the 48 mg dose level, with no serious adverse events reported, and most gastrointestinal adverse events were mild to moderate, indicating the drug's safety in clinical applications.
See More
MetaVia's DA-1726 Shows Significant Weight Loss Results
- Significant Weight Loss: Participants in the 48 mg cohort achieved a mean body weight reduction of 9.1% by Day 54, with no evidence of a plateau throughout the trial, indicating the drug's sustained efficacy in weight management and potential as a new obesity treatment option.
- Waist Circumference Reduction: The cohort experienced an average waist circumference reduction of 9.8 cm by Day 54, with a 5.8 cm reduction at Day 26, both significantly outperforming the placebo group, highlighting DA-1726's potential in improving metabolic health.
- Liver Health Improvements: Exploratory FibroScan assessments indicated significant liver-related improvements, including a 20.0 dB/m reduction in controlled attenuation parameter (CAP) in the 48 mg group, suggesting promising applications for DA-1726 in metabolic dysfunction-associated steatohepatitis (MASH).
- Good Tolerability: DA-1726 demonstrated favorable tolerability at the 48 mg dose level, with no serious adverse events reported, and gastrointestinal side effects were primarily mild to moderate, underscoring the drug's safety profile in clinical applications.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
MetaVia Updates on Obesity and Metabolic Therapies at Emerging Growth Conference
- Management Presentation: MetaVia Inc.'s CEO Hyung Heon Kim and CFO Marshall H. Woodworth will present the company's latest advancements in obesity and metabolic therapies at the Emerging Growth Conference on June 11, 2026, which is expected to attract investor and industry attention.
- New Drug Development: MetaVia is developing DA-1726, a novel oxyntomodulin (OXM) analogue that acts as a dual agonist for GLP-1 and GCGR, showing best-in-class potential for weight loss, glucose control, and waist reduction, potentially outperforming existing GLP-1 receptor agonists.
- Clinical Trial Results: In a Phase 1 multiple ascending dose trial for obesity, DA-1726 demonstrated superior weight loss effects, indicating a promising outlook for treating obesity and potentially providing significant market opportunities for the company.
- Metabolic Disease Treatment: MetaVia's vanoglipel (DA-1241), as a GPR119 agonist, showed positive effects on liver inflammation, lipid metabolism, and glucose metabolism in preclinical studies, potentially offering a new treatment option for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
See More
MetaVia Announces Updates on Obesity and Metabolic Therapies
- Management Presentation: MetaVia Inc. will present updates on its novel obesity and metabolic therapies at the Emerging Growth Conference on June 11, 2026, at 3:25 PM ET, featuring insights from CEO Hyung Heon Kim and CFO Marshall H. Woodworth, showcasing the company's innovative advancements in cardiometabolic diseases.
- DA-1726 Clinical Trial: In a Phase 1 multiple ascending dose trial for obesity, DA-1726 demonstrated best-in-class potential for weight loss, glucose control, and waist reduction, functioning as a dual agonist for GLP-1 and GCGR, potentially outperforming selective GLP-1 receptor agonists like semaglutide in weight management.
- Positive Effects of Vanoglipel: As a novel GPR119 agonist, vanoglipel showed positive effects on liver inflammation, lipid metabolism, and glucose metabolism in preclinical studies, reducing hepatic steatosis, inflammation, and fibrosis, while also demonstrating direct hepatic action in a Phase 2a clinical study.
- Virtual Conference Logistics: Attendees can submit questions in advance, and a Q&A session will follow the presentation, while those unable to join live can access an archived webcast on MetaVia's events page, enhancing investor engagement and transparency.
See More
Rita Ferro Takes Charge of Disney's Global Advertising
- Leadership in Advertising: Rita Ferro, as President of Global Advertising at Disney, leverages her 29 years of industry experience to enhance the company's advertising sales across traditional TV, streaming, and digital platforms, thereby strengthening its position in a competitive media landscape.
- Strategic Integration: Ferro emphasizes the 'One Disney' strategy, creating more compelling advertising opportunities by integrating brand partnerships with movie studios and park activations, which enhances customer engagement and brand loyalty.
- International Expansion: Ferro plans to promote ad-supported streaming business internationally, particularly focusing on local content investments for Disney+, aiming to capitalize on the diversity and growth potential of international markets to drive global business development.
- Tech-Driven Approach: Ferro has spearheaded the restructuring of Disney's ad tech stack, enabling advertisers to target more effectively and improving measurement capabilities, thus enhancing the company's competitiveness in the digital advertising space.
See More
MetaVia's DA-1726 Shows Significant Weight Loss Results
- Significant Weight Loss: The 48 mg cohort achieved a mean body weight reduction of 9.1% at Day 54, with a 6.1% reduction at Day 26, indicating a sustained weight loss trend that underscores DA-1726's potential in obesity treatment.
- Waist Circumference Reduction: Participants in the 48 mg group experienced a significant waist circumference reduction of 5.8 cm at Day 26 and 9.8 cm at Day 54, demonstrating statistical significance compared to the placebo group, further supporting DA-1726's application in improving metabolic health.
- Liver Health Improvements: Exploratory FibroScan assessments indicated significant liver-related improvements in the 48 mg group at Day 54, including a reduction in controlled attenuation parameter (CAP) by 20.0 dB/m, suggesting DA-1726's positive impact on metabolic dysfunction-associated steatohepatitis (MASH).
- Good Tolerability: DA-1726 showed favorable tolerability at the 48 mg dose level, with no serious adverse events reported, and most gastrointestinal adverse events were mild to moderate, indicating the drug's safety in clinical applications.
See More
MetaVia's DA-1726 Shows Significant Weight Loss Results
- Significant Weight Loss: Participants in the 48 mg cohort achieved a mean body weight reduction of 9.1% by Day 54, with no evidence of a plateau throughout the trial, indicating the drug's sustained efficacy in weight management and potential as a new obesity treatment option.
- Waist Circumference Reduction: The cohort experienced an average waist circumference reduction of 9.8 cm by Day 54, with a 5.8 cm reduction at Day 26, both significantly outperforming the placebo group, highlighting DA-1726's potential in improving metabolic health.
- Liver Health Improvements: Exploratory FibroScan assessments indicated significant liver-related improvements, including a 20.0 dB/m reduction in controlled attenuation parameter (CAP) in the 48 mg group, suggesting promising applications for DA-1726 in metabolic dysfunction-associated steatohepatitis (MASH).
- Good Tolerability: DA-1726 demonstrated favorable tolerability at the 48 mg dose level, with no serious adverse events reported, and gastrointestinal side effects were primarily mild to moderate, underscoring the drug's safety profile in clinical applications.
See More
Biotech Stocks Surge with Akari Leading the Rally
- Akari Therapeutics Surge: Akari Therapeutics (AKTX) soared over 255% on Friday, marking its second consecutive day of gains following the announcement of breakthrough preclinical data for its drug AKTX-101, which demonstrated synergistic effects in KRAS-mutated pancreatic cancer models, highlighting significant advancements in oncology.
- MetaVia Clinical Progress: MetaVia Inc. (MTVA) rose over 34% on Friday as the company advances its DA-1726 in a Phase 1 trial for treating cardiometabolic diseases, with an end-of-Phase 2 meeting with the FDA planned, indicating strong potential in the cardiometabolic sector.
- GeoVax Vaccine Development: GeoVax Labs Inc. (GOVX) increased over 32% on Friday amid a growing Ebola outbreak, as the company progresses its vaccine development against Ebola and Marburg viruses, with a pivotal Phase 3 study of its GEO-MVA candidate set to begin in Q4 2026, underscoring its role in addressing public health emergencies.
- Polyrizon Clinical Agreement: Polyrizon Ltd. (PLRZ) gained over 20% on Friday after signing its first Clinical Trial Agreement for NASARIX Allergy Blocker, aimed at treating seasonal allergic rhinitis, marking a significant step towards initiating its first-in-human clinical study and showcasing its innovative potential in biotechnology.
See More
